From Novarad touting its VR-surgical guidance system to Zynex paying off its $2.2M loan, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Stimwave announces first patient in Brazil Stimwave announced in a July 5 press release that its first patients in Brazil have received Stimwave’s wireless pain relief […]
Pain Management
NeuroMetrix raises $7m
NeuroMetrix (NSDQ:NURO) said on Monday it inked a private placement deal set to bring in approximately $7 million in gross proceeds. Money in the placement came through the sale of 7,000 shares of Series F convertible preferred stock at $1,000 per share. Funds will be supplied through in initial tranche of $3.5 million and a second tranche, which […]
BioDelivery Sciences, Purdue ink exclusive distribution deal for Belbuca in Canada
BioDelivery Sciences International (NSDQ:BDSI) said today that it inked an exclusive distribution deal with Purdue Pharma‘s Canada branch for the licensing, distribution, marketing and sale of Belbuca in Canada. The company’s Belbuca buccal film was designed to deliver buprenorphine for patients with chronic pain. It was cleared by Health Canada in June for patients with pain severe enough to necessitate […]
Endo pulls painkiller from the market following FDA request
Endo Pharmaceuticals (NSDQ:ENDP) said today that it will voluntarily pull its Opana ER painkiller from the market. The move comes just weeks after the FDA asked the company to pull the plug on its opioid, arguing that the benefits of the abuse-deterrent drug no longer outweigh the risks. To write off the remaining net book value of the […]
Study shows no benefit for RF denervation in back pain
A team of researchers from the Netherlands evaluated three clinical trials involving 681 patients with chronic low back pain and found that radiofrequency denervation combined with exercise did not bring about a significant reduction of pain compared to exercise alone after 3 months. Radiofrequency denervation is commonly used to treat chronic low back pain, but […]
Improving VNS therapy: ElectroCore CEO Amato on gammaCore and its slated July launch
Neuroscience tech developer ElectroCore said recently it plans to launch its handheld gammaCore vagus nerve stimulation device in the US in mid-July, after having won clearance from the FDA in April for treating episodic cluster headaches. Unlike other vagus nerve stimulation devices, the gammaCore is an external handheld device with no implanted component, designed to […]
Topical post-herpetic neuralgia treatment fails to meet primary endpoint in Phase II
Teva Pharmaceuticals (NYSE:TEVA) and Xenon Pharmaceuticals (NSDQ:XENE) said this week that the Phase II study of a topical post-herpetic neuralgia treatment did not meet its primary or secondary endpoints. The small-molecule inhibitor, TV-45070, was licensed by Xenon to Teva in December 2012. Get the full story at our sister site, Drug Delivery Business News.
Semnur touts Phase I/II trial of non-opioid pain-killer
Semnur Pharmaceuticals touted data today from a Phase I/II pharmacokinetic trial of its injectable, non-opioid pain-killer, SP-102. The trial enrolled 12 patients with radicular pain. The trial met its primary endpoint and showed that single epidural injection of SP-102 could provide a sustained analgesic effect for 1 month. Get the full story at our sister […]
Camarus, Braeburn tout Phase II data for long-acting buprenorphine depot
Camarus AB (STO:CAMX) and Braeburn Pharmaceuticals touted data yesterday from a Phase II trial of its long-acting buprenorphine depot. The 47-patient trial found that CAM2038 blocks the effects of opioids and suppresses withdrawal symptoms in adults with opioid use disorder. The in-patient trial included 5 3-day test sessions to evaluate the patients’ response to randomized […]
BioDelivery wins Health Canada approval for Belbuca pain relief product
BioDelivery Sciences International (NSDQ:BDSI) said today that Health Canada approved its buprenorphine hydrochloride buccal film, Belbuca, for the management of pain severe enough to necessitate daily, long-term opioid treatment and for which alternative management options are inadequate. The company said it plans to commercialize Belbuca in Canada through an unnamed partner and that the launch […]
Indivior touts late-stage trial for monthly buprenorphine depot
Indivior (LON:INDV) touted data today from its pivotal Phase III trial for RBP-6000, a once-monthly injectable buprenorphine depot for the treatment of adults with opioid use disorder. The 24-week study met its primary and key secondary endpoints for both dosage regimens, according to the company. Get the full story at our sister site, Drug Delivery […]